Contract Manufacturing

Emergent BioSolutions announced a five-year manufacturing agreement with Johnson & Johnson’s (NYSE:JNJ) Janssen Pharmaceuticals for the parent company’s SARS-CoV-2 vaccine candidate. Gaithersburg, Md.-based Emergent is set to provide contract development and manufacturing services to produce Johnson & Johnson’s Ad26.COV2-S vaccine candidate at scale over five years, with the deal valued at approximately $480 million for…

The U.S. Health and Human Services Dept. and Defense Dept. announced a joint agreement with Novavax  (NSDQ:NVAX) worth $1.6 billion to scale the manufacturing of its COVID-19 vaccine candidate. Gaithersburg, Md.-based Novavax’s commercial-scale manufacturing is expected to produce 100 million doses of the investigational vaccine that would become available for use in clinical trials or,…

Moderna (NSDQ:MRNA) and Catalent (NYSE:CTLT) today announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent’s biologics facility in Bloomington, Ind. Catalent will provide vial filling and packaging capacity, as well as additional staffing required for 24×7 manufacturing operations at the site to support production of an initial 100 million…

The U.S. Dept. of Health & Human Services (HHS) and Dept. of Defense (DoD) announced a joint effort to increase manufacturing for vials earmarked for COVID-19-related drugs and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), as part of HHS, collaborated with DoD to provide funding for U.S.-based companies Corning Inc. and SiO2 Materials…

Sherlock Biosciences announced today that it will collaborate with Integrated DNA Technologies (IDT) to enable large-scale manufacturing of the Sherlock CRISPR SARS-CoV-2 kit for COVID-19 detection. Officials at Cambridge, Mass.–based Sherlock Biosciences think the company’s CRISPR-based diagnostic test, which recently received an FDA emergency use authorization, will increase testing capacity and decreasing time to result…

Merck has exercised its option to use Vaxxas‘ High Density Microarray Patch (HD-MAP) platform as a delivery platform for a vaccine candidate, the companies announced today. The companies did not disclose what the vaccine candidate is supposed to treat. But Merck this month announced two COVID-19 vaccine development efforts: a collaboration with IAVI and plans…

Thermo Fischer Scientific announced today that it has inked a strategic partnership with biotechnology company CSL to help better meet the growing demand for biologic therapies. Thermo Fisher will support CSL’s product portfolio through its pharma services network, including drug product development, biologics manufacturing, sterile fill-finish, packaging and clinical trials logistics. Thermo Fisher — through…

Phlow announced today that it received $354 million in U.S. government funding to manufacture essential medicines at risk of shortage, including those involved in the COVID-19 pandemic response. Richmond, Va.–based Phlow’s manufacturing is being funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the office of Assistant Secretary for Preparedness and Response (ASPR)…

Pfizer is turning to its 200-strong network of outside contractors to make more of its existing medicines as it prepares for a potential COVID-19 vaccine, according to media reports. The New York–based pharmaceutical giant said May 5 that it will invest at-risk to produce millions of doses of a coronavirus vaccine in 2020, boosting production…

Evonik recently announced that it will spend an initial €25 million (equivalent to nearly $28 million) to expand its Dossenheim and Hanau facilities in Germany. The expansion is meant to meet the growing demand for the contract manufacturing of active pharmaceutical ingredients (APIs) and advanced intermediates within Europe. Evonik expects to complete the €25 million…